Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q2 2020

Q2 2020 biggest moves
  • AHCOAHCO

    AdaptHealth

    Cut 92%

    now 0.7% of portfolio

  • HZNPHZNP

    HORIZON THERAPEUTICS PUB L

    Cut 67%

    now 3.2% of portfolio

  • HOLXHOLX

    HOLOGIC

    New

    2.3% of portfolio

  • LRMRLRMR

    Larimar Therapeutics

    New listing

    1.9% of portfolio

89 changes in all

Top Holdings93 positions

Checking export access…
Activity:
144.8M$280.6M8.2%——
3 qtrssince 2019-Q4
Unchanged
0
MYL
MYLDelisted

MYLAN NV

12.2M$195.4M5.7%——
3 qtrssince 2019-Q4
Unchanged
0
??
NEVRO CORPDelisted
Bond
115.8M$157.8M4.6%——
3 qtrssince 2019-Q4
Unchanged
0
SDGR

Schrodinger, Inc.

1.3M$123.3M3.6%$43.12+112.36%
2 qtrssince 2020-Q1
Unchanged
0
DF
DFPHUDelisted
Unit

DFP HEALTHCARE ACQUISITNS CO

10.5M$111.7M3.3%——
2 qtrssince 2020-Q1
Unchanged
0
HZNP
HZNPDelisted

HORIZON THERAPEUTICS PUB L

2M$108.4M3.2%——
3 qtrssince 2019-Q4
Decreased
0
??
NUVASIVE INCDelisted
Bond
85M$93.1M2.7%——
2 qtrssince 2020-Q1
Unchanged
0
IMMU
IMMUDelisted

IMMUNOMEDICS INC

2.6M$90.8M2.6%——
3 qtrssince 2019-Q4
Decreased
0
PCRX

Pacira BioSciences, Inc.

1.7M$87.3M2.5%$33.93+54.62%
2 qtrssince 2020-Q1
Increased
52
??
DEXCOM INCDelisted
Bond
34M$84.3M2.5%——
3 qtrssince 2019-Q4
Unchanged
0
HOLX
HOLXDelisted

HOLOGIC INC

1.4M$78.1M2.3%——
1 qtr
New
77
MYOK
MYOKDelisted

MYOKARDIA INC

704,000$68M2.0%——
3 qtrssince 2019-Q4
Increased
75
MIRM

Mirum Pharmaceuticals, Inc.

3.4M$67.1M2.0%$24.52-20.64%
3 qtrssince 2019-Q4
Unchanged
0
LRMR

Larimar Therapeutics, Inc.

5.1M$66.1M1.9%$12.850.00%
1 qtr
New
68
??
INSMED INCDelisted
Bond
61M$59.3M1.7%——
2 qtrssince 2020-Q1
Unchanged
0
RVMD

Revolution Medicines, Inc.

1.8M$56.7M1.7%$21.91+44.09%
2 qtrssince 2020-Q1
Unchanged
0
CNC

Centene Corporation

886,000$56.3M1.6%$62.44+1.78%
3 qtrssince 2019-Q4
Decreased
0
RYTM

Rhythm Pharmaceuticals, Inc.

2.5M$55.1M1.6%$22.96-2.87%
3 qtrssince 2019-Q4
Decreased
0
SWTX
SWTXAcquired

SPRINGWORKS THERAPEUTICS INC

1.2M$51.8M1.5%——
3 qtrssince 2019-Q4
Increased
66
AXNX
AXNXDelisted

AXONICS INC

1.4M$49.5M1.4%——
3 qtrssince 2019-Q4
Decreased
0
$3.4B
AUM
93
Positions
Q2 2020
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2020-Q1$3,151,113,0000.539146165786%
2020-Q2$3,433,887,0008.97378164477%
Activity profile
$ moved · Q2'20
New29%Increased13%Decreased38%Exited20%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 3.1 quarters
<1Q25%1-4Q53%1-2Y0%2Y+23%

Deerfield Management Company, L.P. manages $3.4B across 93 positions as of Q2 2020. Top holdings: HORIZON PHARMA INV LTD (8.2%), MYL (5.7%), NEVRO CORP (4.6%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$3B
HORIZON PHAR8.17%
MYL5.69%
NEVRO CORP4.60%
SDGR3.59%
DFPHU3.25%
HZNP3.16%
NUVASIVE INC2.71%
IMMU2.64%
PCRX2.54%
DEXCOM INC2.46%
Other2.27%

Portfolio allocation by GICS sector

Sectors3
Unknown50.79%
Healthcare48.47%
Financial Services0.74%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Unknown, Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used